WEST CHESTER, Pa. – Chiral Technologies, Inc., part of DAICEL CORPORATION, the global market leader in enantioselective chromatography, announced that Sergey Smulevitch, Ph.D., has joined the company as Technology Director.

In this position, Dr. Smulevitch will be responsible for planning and directing all aspects of CTI’s technology activities, including product development for the newly acquired Diffinity Genomics®business unit.

Reporting to Joseph Barendt, Ph.D., Chief Operating Officer, Dr. Smulevitch also will act as CTI’s liaison within Daicel’s global technology network and provide leadership to CTI with respect to pursuing new products and technologies.

“Dr. Smulevitch brings with him a wealth of experience in nucleic acids technologies, which will be hugely beneficial to the Diffinity® business. In addition, with his knowledge and experience in Life Sciences, including chromatography, we look forward to his contributions to our overall business activities,” stated Dr. Barendt.

“Expertise in separation media chemistry is the reason for Chiral Technologies’ position as the global market leader. This expertise has a great synergy with the Diffinity technology, and offers an opportunity for innovative product development in the field of Life Sciences.” Dr. Smulevitch said.

Previously, Dr. Smulevitch worked for Roche Diagnostics developing PCR assays, trouble shooting technical problems in their genomics product line, providing customer training and technical support, and supervising product development. Prior to Roche, he had worked for Digene, the National Cancer Institute, and the New York University School of Medicine among others.

Dr. Smulevitch received a Ph.D. in Chemistry/Biochemistry Molecular Biology from the Moscow State University and a B.S. in Chemical Engineering from the Moscow University of Chemical Technology.